Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.
Adverse effects
Serious adverse drug reactions associated with clopidogrel therapy include:Severe neutropenia (Incidence: 1/2,000)Thrombotic thrombocytopenic purpura (TTP) (Incidence: 4/1,000,000 patients treated)[citation needed]Hemorrhage - The incidence of hemorrhage may be increased by the co-administration of aspirin.[9] Gastrointestinal Hemorrhage (Incidence: 2.0%)Cerebral Hemorrhage (Incidence: 0.1 to 0.4%)Use of non-steroidal anti-inflammatory drugs is discouraged in those taking clopidogrel due to increased risk of digestive tract hemorrhage
Serious adverse drug reactions associated with clopidogrel therapy include:Severe neutropenia (Incidence: 1/2,000)Thrombotic thrombocytopenic purpura (TTP) (Incidence: 4/1,000,000 patients treated)[citation needed]Hemorrhage - The incidence of hemorrhage may be increased by the co-administration of aspirin.[9] Gastrointestinal Hemorrhage (Incidence: 2.0%)Cerebral Hemorrhage (Incidence: 0.1 to 0.4%)Use of non-steroidal anti-inflammatory drugs is discouraged in those taking clopidogrel due to increased risk of digestive tract hemorrhage
No comments:
Post a Comment